*Highlights from BIO International 2024* PDX Pharmaceuticals had a fantastic week at BIO International earlier this month in San Diego! Our Head of Research & COO, Dr. Worapol (Boom) Ngamcherdtrakul, delivered a presentation on our cutting-edge Pdx-NP™ nanoparticle technology, and our lead cancer immunotherapeutic candidate ARAC-02™. The presentation sparked meaningful discussions about how our technology addresses the limitations of lipid nanoparticles, enables targeted co-delivery of various therapeutic classes, and stimulates an anti-tumor immune response. Thank you to everyone who joined us and engaged in enriching dialogues, both following the talk and in scheduled one-on-one meetings. We are excited about the possibilities ahead and look forward to continuing our collaborative efforts. Stay connected for more updates! Photo courtesy -- Julie Black, Oregon Bioscience Association; and thank you OBA for supporting Oregon's Biotech companies! #BIO2024 #Cancer #Innovation #Nanotechnology
PDX Pharmaceuticals’ Post
More Relevant Posts
-
Last week, our CEO, Dr. Wassana Yantasee, and our Head of Research & COO, Dr. Worapol (Boom) Ngamcherdtrakul, shared their expertise by serving on the NIH Scientific Review Panels for ‘UG3/UH3 - Cancer Adoptive Cellular Therapy Network for Pediatric Cancers’ and ‘Small Business: Biomaterials, Delivery, and Nanotechnology,’ respectively. PDX Pharma is proud to contribute to groundbreaking advancements in cancer research. #NIH #CancerResearch #Nanotechnology
-
Congratulations to Dr. Wassana Yantasee and her OHSU team for winning the Circle of Giving's Women’s Health Award for their development of a new interleukin-2 (IL-2) cancer therapy based on our Pdx-NP™. This work showcases the capability of the Pdx-NP™ platform in delivering and co-delivering various therapeutic modalities, ranging from oligos, antibodies, small molecule drugs, adjuvants, peptides, proteins, to cytokines. PDX Pharma will continue our collaboration with OHSU for translating this technology to patients.
We are grateful to receive a generous grant from The OHSU Center for Women’s Health Circle of Giving, which will fund our development of nano-based interleukin-2 (IL-2) for the treatment of triple-negative breast cancer and ovarian cancer. The work is part of Ruijie Wang's PhD thesis project. Thanks for the support from our co-investigators, Drs. Shivaani Kummar and Megan Burger. Current IL-2 treatments are administered several times a day for up to a week due to its short half-life. Our Pdx-NP nano-platform can prolong the half-life, protect IL-2 from degradation, and promote IL-2 uptake by T cells. We achieve a 40-fold increase in desired CD8+ T cells over undesired Treg cells, leading to a 100% cure rate of tumor-bearing mice when combined with immune checkpoint inhibitors (ICIs). We propose to combine an ICI and IL-2 on our nano-platform to create a single agent that will enhance treatment efficacy while reducing toxicity and the patient's burden. We have submitted a fast-track SBIR grant application to further its development in collaboration with PDX Pharmaceuticals. https://lnkd.in/g4PtDW57
-
Next week, PDX Pharmaceuticals will be at BIO International 2024 in San Diego, June 3-6. Dr. Ngamcherdtrakul, Head of Research & COO, will present our nano-immunotherapy platform technology on Monday, June 3, at 2:45 PM. Details of the talk can be found here: https://lnkd.in/dMq8Nqb3. #BIO2024 We're excited to explore possibilities for partnership, collaboration, and investment. Please connect with us via DM or the BIO partnering system. https://lnkd.in/eEDtKaAK
PDX Pharmaceuticals
convention.bio.org
-
We're proud to share that two of our amazing Research Assistants are heading to medical school this fall! Alyssa Wallstrum will be attending the University of Toledo's MD/PhD program, and Natalie White will be joining the OHSU School of Medicine. PDX Pharma is very proud to be training talented young scientists and preparing them for higher education. To date, three of our Research Assistants have been accepted into medical schools and three into PhD programs.
-
PDX Pharmaceuticals has received a Notice of Allowance for the third US patent for our ARAC™ technology. ARAC™ is based on our nanoparticle platform, Pdx-NP™, co-delivering antigen release agents and immune checkpoint inhibitors to create robust anti-tumor immune response. First in the pipeline is ARAC-02™, which combines a PD-L1 antibody, a PLK1 inhibitor, and an immune-stimulant CpG to elicit a potent antitumor immune response, particularly through the activation of CD8+ T cells. This multifaceted approach has shown promising results in preclinical studies, with the potential to transform the landscape of lung cancer treatment. With this latest patent allowance, we are not only extending our protection but also demonstrating our ongoing commitment to advancing our ARAC™ pipeline. We're incredibly proud of this achievement and grateful for the support of our team and partners. Stay tuned for updates! #ARAC #PatentAllowed #Innovation
-
PDX Pharmaceuticals will attend BIO International 2024 in San Diego, California, from June 3-6, 2024! #BIO2024 Dr. Worapol Ngamcherdtrakul, Head of Research & COO, will be presenting on Monday, June 3, at 2:45 PM in Company Presentation Theater 4, Hall A (Oncology session). PDX Pharmaceuticals has an innovative patented nano-delivery platform, Pdx-NP™, which is engineered to overcome the liver-homing propensity of lipid nanoparticles and create next-generation cancer treatments. Supported by $10M in grants from the NIH, this platform efficiently co-delivers a wide range of therapeutics, including siRNA, antisense, antibodies, drugs, immunotherapy, and adjuvants, demonstrating efficacy in multiple tumor models. Our lead candidate, ARAC-02™, co-delivers a PLK1 inhibitor, adjuvant CpG, and a PDL1 antibody, effectively targeting tumors and inducing a potent anti-tumor immune response. ARAC-02 overcomes resistance to standard immunotherapy, and achieves cures in preclinical lung cancer models. We are excited to share our progress and IND/clinical trial plans at BIO International. #nanomedicine #immunotherapy #platform #precisionmedicine We are eager to explore partnership, collaboration, and investment opportunities to create impactful medicine addressing unmet needs. Given the flexibility of Pdx-NP™, we welcome partnerships with other companies to co-develop novel nano-based therapeutic or vaccine candidates for cancer and beyond. We look forward to connecting with you there! Please reach out via messaging or through the BIO partnering system. https://lnkd.in/eEDtKaAK
-
-
👏 Congratulations to Dr. Wassana Yantasee, CEO of PDX Pharmaceuticals, for being inducted into The National Academy of Inventors! PDX Pharma also filed a new provisional patent application for their nanoparticle delivery of cytokines to treat cancer and autoimmune diseases. Exciting times ahead for PDX Pharma! #Innovation #Research #OBI4You
-
-
On April 3, 2024, Dr. Worapol Ngamcherdtrakul (COO) took the stage at the MedInvest Biotech & Pharma Investor Conference in NYC. It was an exciting opportunity to showcase our groundbreaking patented drug delivery platform, PDX-NP™. Developed as an alternative to lipid nanoparticles (LNPs) that primarily home to the liver, our non-lipid PDX-NP™ can load multiple cargo types simultaneously and target both cancer and immune cells in tissues beyond the liver, revolutionizing the landscape of targeted therapy and immunotherapy for cancer. Our lead therapeutic candidate, ARAC-02™, not only kills cancer cells, but also stimulates an anti-tumor immune response, providing more effective and durable tumor control in preclinical models. We are proud of the exciting advancements our team is making! It was also inspiring to hear from and connect with the investment community and other biotech companies, whose missions are to revolutionize healthcare. #immunotherapy #nanotechnology #biotech #cancerresearch See a recording of Dr. Ngamcherdtrakul's talk at: https://lnkd.in/gFCjVxEk
PDX Pharmaceuticals - Worapol Ngamcherdtrakul
https://www.youtube.com/
-
We’re delighted to share that we’ve been selected as recipients of the Small Business Innovation Research (SBIR) Matching Grant from Business Oregon. These programs are vital for fostering innovation and providing opportunities for small businesses like ours to develop groundbreaking technologies with commercialization potential. This grant, funded with Oregon State Lottery Funds administered by OBDD, will support the development of our patented nano-immunotherapy, ARAC™, targeting solid tumors, and bolster our efforts to bring it to market. We're grateful for this support and excited for the journey ahead. Stay tuned for updates! #CancerResearch https://lnkd.in/gsbaqPKY
Biotech CEO, Strategic Adviser & Board Director
2wCongrats Worapol (Boom) Ngamcherdtrakul & the PDX team! The field needs viable alternatives to LNPs, and the PDX nanoparticle platform offers a compelling & differentiated delivery engine.